title: Changes in CD4+ T-cell differentiation phenotype during structured treatment interruption in patients with chronic HIV-1 infection.
abstract: Markers of maturation and activation were measured on peripheral CD4+ T cells in chronically HIV-1-infected patients in a randomized, controlled pilot study of structured treatment interruption (STI). Eight subjects underwent 2 cycles of 1 month off and 1 month on highly active antiretroviral therapy (HAART), followed by a final 3-month interruption. During STI, CD4+ T-cell percentage remained relatively stable in 4 of 8 subjects. The remaining 4 STI subjects had significant rapid decline in CD4+ T-cell percentage during STI, followed by return to pre-STI baseline while on HAART. Changes in overall CD4+ T-cell percentage corresponded with fluctuations in the CD45RA+CCR7+ naive and CD45RA-CCR7+ central memory subsets. Subjects with variable CD4+ T-cell percentages tended to have higher pre-HAART plasma HIV-1 RNA set-points and experienced higher levels of plasma HIV-1 RNA rebound during STI. These results suggest that interruptions should be avoided whenever possible in patients on HAART with high plasma HIV-1 RNA set-points.
authors.affiliation: Duke University Medical Center, Durham, NC 27705, USA.
authors.forename: Thomas H
authors.initials: TH
authors.lastname: Alexander
authors.forename: Gabriel M
authors.initials: GM
authors.lastname: Ortiz
authors.forename: Melissa F
authors.initials: MF
authors.lastname: Wellons
authors.forename: Andrew
authors.initials: A
authors.lastname: Allen
authors.forename: Edward J
authors.initials: EJ
authors.lastname: Grace
authors.forename: Becky
authors.initials: B
authors.lastname: Schweighardt
authors.forename: Jason
authors.initials: J
authors.lastname: Brancato
authors.forename: Johan K
authors.initials: JK
authors.lastname: Sandberg
authors.forename: Scott N
authors.initials: SN
authors.lastname: Furlan
authors.forename: G Diego
authors.initials: GD
authors.lastname: Miralles
authors.forename: Douglas F
authors.initials: DF
authors.lastname: Nixon
authors.forename: John A
authors.initials: JA
authors.lastname: Bartlett
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000276:immunology*; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology* / Q000473:pathology; D002454:Cell Differentiation / Q000276:immunology; D004334:Drug Administration Schedule; D015497:HIV-1 / Q000235:genetics / Q000302:isolation & purification; D006801:Humans; D016130:Immunophenotyping; D008213:Lymphocyte Activation / Q000276:immunology; D012367:RNA, Viral / Q000097:blood; D012016:Reference Values; D019562:Viral Load
chemical_list: D012367:RNA, Viral